Genesis Therapeutics

ICYMI: #ICML2025 was a fantastic week spent discussing cutting-edge research and connecting with our AI/ML community. Thanks to the team behind the [ICML] Int'l Conference on Machine Learning for having our Director of Machine Learning, Maruan Al-Shedivat, and Staff Machine Learning Research Scientist, David Li-Bland, onsite to contribute to meaningful conversations on how AI can accelerate drug discovery and deepen biological understanding. If you missed our talks, visit our website to learn how we’re unifying machine learning and physics to drive breakthroughs in biology and medicine: https://lnkd.in/gN77MHA9

Join us at [ICML] Int'l Conference on Machine Learning 2025! On Friday, July 18th, Genesis’ Director of Machine Learning, Maruan Al-Shedivat, and Machine Learning Research Scientist, David Li-Bland, will be participating in the Generative AI and Biology (GenBio) Workshop to discuss how AI is accelerating breakthrough drug discovery, protein research and more. If you’re attending #ICML2025 and interested in how we’re pushing the boundaries of small molecule drug discovery, check out this timely workshop 👉 https://lnkd.in/gDFbmumG

Are you heading to [ICML] Int'l Conference on Machine Learning next week? Our machine learning team will be on the ground in Vancouver to connect with fellow researchers, engineers, and scientists advancing the fields of biology and drug discovery using AI. If you’re attending #ICML2025 and interested in a coffee chat ☕ with our ML team, sign up here: https://lnkd.in/g4_8VigH

Join us in welcoming Joe L. to Genesis! We’re excited to continue the expansion of our leadership and technical teams by appointing Joe as our new Head of Platform Engineering. From scaling two multibillion-dollar ad products at Meta to building the AI/ML foundations for autonomous vehicle behavior planning at Cruise, he brings over a decade of experience in AI/ML platforms, distributed systems, and large-scale product engineering Learn more about our Genesis team, open roles, and work building industry-leading platforms to power AI-driven drug discovery on our website: https://lnkd.in/gK-P_D4f

Axios featured AI drug discovery and development as one of the hottest industries in the life sciences, including our work at Genesis to advance cancer and autoimmune therapies with AI as well as collaborations with tech leaders like NVIDIA and pharma companies. Our CEO Evan Feinberg says, “Through our partnerships, we can cast a much wider net, both in just the volume of diseases and drug targets we can work on, but also the therapeutic areas as well.” Thanks to biotech deals reporter Katherine Davis for the highlight. Read the full article in Axios: https://lnkd.in/grd8rHqR

This Wednesday, our Head of Computational Chemistry, Michael V. LeVine, will be speaking on a panel at the Molecular Machine Learning (MoML) Conference at Mila - Quebec Artificial Intelligence Institute. He and other leading researchers will explore how machine learning is transforming molecular modeling and therapeutic design. If you're interested in the intersection of AI and drug discovery, learn more about the event here: https://portal.ml4dd.com/

We are enthusiastic to announce Aleksandra Faust as our Chief AI Officer. She brings over two decades of leadership in AI and tech, most recently as Director of Research at Google DeepMind, to our GEMS platform and research teams pioneering molecular AI. In her tenure at DeepMind, Dr. Faust oversaw foundational model learning research, and contributed to Gemini and to generalist web agents, among many other key innovations. Read the full announcement in our press release: https://lnkd.in/gvxCwT5d

Great to see our AI platform collaboration with Incyte highlighted in the Delaware Business Times. Our teams have partnered to accelerate the discovery of breakthrough small molecule medicines using our GEMS platform. Check out the full article here, including commentary from Incyte President and Head of Research Development Pablo Cagnoni: https://lnkd.in/gifth3ZD

We had a great time at #ICLR2025 sharing Genesis’ advances in applying cutting-edge machine learning and AI to develop therapies with unprecedented accuracy and precision. Big thanks to Pranav Murugan and James (Korrawat) Pruegsanusak for representing our team. If you missed our panel sessions, check out our website to learn more about what we’re building at Genesis: https://lnkd.in/gG3_pabc

Genesis is heading to the University of Waterloo for the first time! We’re looking forward to connecting with talented students and sharing what makes Genesis such a dynamic place to grow a career. If you’re a student curious about what we’re building—or just want to chat about AI Drug Discovery—come say hello! 👋 #Waterloo #UniversityRecruiting #TechCareers